作者:Reem F. Abutayeh、Jehad Almaliti、Mutasem O. Taha
DOI:10.2174/1573406415666190401144053
日期:2020.4.17
most prominently associated with acute myeloid leukemia (AML). Flt3-specific inhibitors have shown promising results in interfering with AML. METHODS The crystallographic structures of two inhibitors complexed within Flt3, namely, quizartinib and F6M, were used to guide the synthesis of new sulfonamide-based Flt3 inhibitors. RESULTS One of the prepared compounds showed low micromolar anti-Flt3 bioactivity
背景技术Flt3是涉及不同白血病的致癌激酶。它与急性髓细胞性白血病(AML)最明显相关。Flt3特异性抑制剂在干扰AML方面显示出令人鼓舞的结果。方法使用两种在Flt3中复合的抑制剂,即quizartinib和F6M的晶体学结构,指导新的基于磺酰胺的Flt3抑制剂的合成。结果制备的化合物之一显示出低的微摩尔抗Flt3生物活性,并且有趣的是,其对相关的致癌激酶VEGFR2的低微摩尔生物活性。结论磺酰胺已成功地用作特权支架,用于合成新型的Flt3微摩尔效价抑制剂。